
Annual report 2024
added 03-21-2026
Tiziana Life Sciences PLC Net Debt 2011-2026 | TLSA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Tiziana Life Sciences PLC
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -3.94 M | 186 K | -4.48 M | -8.69 M | -2.06 M | 169 K | -4 K | -33 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 186 K | -8.69 M | -2.36 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Altimmune
ALT
|
-9.22 M | $ 3.41 | 2.1 % | $ 300 M | ||
|
Amgen
AMGN
|
41 B | $ 350.17 | 0.68 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 19.57 | 0.36 % | $ 915 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 217.82 | -1.83 % | $ 5 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.4 | 1.82 % | $ 357 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.64 | 1.15 % | $ 16.6 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Benitec Biopharma
BNTC
|
-1.92 M | $ 11.0 | 0.18 % | $ 453 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.58 | 3.62 % | $ 185 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.35 | 0.3 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
-85.6 M | $ 12.83 | 0.71 % | $ 773 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
-9.78 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
CorMedix
CRMD
|
-143 M | $ 6.29 | 0.64 % | $ 453 K | ||
|
CytomX Therapeutics
CTMX
|
-28.7 M | $ 4.41 | -1.01 % | $ 608 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.12 | 1.2 % | $ 198 M | ||
|
Denali Therapeutics
DNLI
|
-158 M | $ 20.92 | 3.69 % | $ 3.44 B | ||
|
Dyadic International
DYAI
|
-6.38 M | $ 0.89 | -5.85 % | $ 25.6 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.26 | 0.47 % | $ 707 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M |